Device Pain Management

Nalu Neurostimulation System

Payments companies reported to CMS as associated with Nalu Neurostimulation System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.5Massociated payments (2023-2025)
5,669clinicians with associated payments
1company reporting

By year

2023 $759K
2024 $823K
2025 $884K

Payments reported as associated with Nalu Neurostimulation System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Pain Medicine (Anesthesiology) $657K
Interventional Pain Medicine $618K
Pain Medicine $248K
Pain Medicine (Physical Medicine & Rehabilitation) $163K
Family $153K
Physician Assistant $152K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Nalu Neurostimulation System

These are the largest totals companies reported as associated with Nalu Neurostimulation System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
John Hatheway Coeur D Alene, ID Interventional Pain Medicine $196,834.21
Eric Cornidez Tucson, AZ Pain Medicine $164,597.95
Usman Latif Kansas City, KS Pain Medicine (Anesthesiology) $162,076.13
Mehul Desai Washington, DC Pain Medicine (Physical Medicine & Rehabilitation) $119,513.53
Sailesh Arulkumar Oklahoma City, OK Pain Medicine (Anesthesiology) $103,372.97
Ali Valimahomed Holmdel, NJ Interventional Pain Medicine $98,661.84
Timothy Ratino Fort Worth, TX Interventional Pain Medicine $78,859.61
Armen Haroutunian Westlake Village, CA Pain Medicine (Anesthesiology) $75,189.97
Evan Peskin Flint, MI Interventional Pain Medicine $56,942.85
Lindsay Carter Tucson, AZ Family $40,344.43

Prescribed Nalu Neurostimulation System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.